[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"contraceptive-usage\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:contraceptive-usage":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,45,71,96,120],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100634950","peer-led-service-delivery-model-for-pregnant-and-lactating-adolescent-girls-and-young-women-in-zimbabwe-100634950",false,"NCT07546344","Peer-led Service Delivery Model for Pregnant and Lactating Adolescent Girls and Young Women in Zimbabwe","Peer-led Service Delivery Model to Increase HIV Prevention and Contraception in Pregnant and Lactating Adolescent Girls and Young Women in Zimbabwe: a Pilot Study","Ontanga","Inclusion Criteria:\n\n* either pregnant or have at least one child who is less than 18 months of age at the time of initial engagement\n* Aged 15 - 24 years old",true,"FEMALE","15 Years","24 Years",{"count":22,"type":23},600,"ESTIMATED","INTERVENTIONAL",[26],"NA","This is a pilot cluster-randomized control trial co-led by Dr. Valentina Cambiano, Associate Professor of Epidemiology at University College London, UK and Professor Euphemia Sibanda, Research Director at the Centre for Sexual Health and HIV Research (CeSHHAR Zimbabwe). The goal of the proposed study is to evaluate the appropriateness, feasibility, acceptability, uptake, costs and cost-effectiveness of a community-based, HIV-status neutral peer-led service delivery model in which young mentor mothers (YMM) work with pregnant and lactating adolescent girls and young women (PL-AGYW, aged 15-24), up to two-years post-birth, in Zimbabwe to promote uptake of contraception and HIV prevention.\n\nYMM living with HIV have been found to be effective in supporting their peers for prevention of mother-to-child transmission of HIV and adherence to treatment through the \"Zvandiri\" programme. The investigators propose adapting the \"Zvandiri\" YMM to include those without HIV to promote behaviour to prevent HIV and unintended pregnancies. This proposed intervention is building on the formative work that had the overall aim of co-developing with AGYW (aged 15-24) a Pre-Exposure Prophylaxis (PrEP) implementation intervention for AGYW who need it, that attracts them to PrEP, and supports pregnant and lactating adolescent girls and young women while taking it.",[29,30,31],"HIV Prevention","Contraceptive Usage","Adherence, Medication","NOT_YET_RECRUITING","2026-04-16",{"date":35,"type":36},"2026-04-22","ACTUAL",{"date":38,"type":23},"2026-04",{"date":40,"type":23},"2027-06",{"name":42,"class":43},"University College, London","OTHER",3,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":17,"sex":52,"minAge":19,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":24,"phases":56,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":70},"100592230","effectiveness-testing-of-a-videogame-intervention-no-baby-no-to-decrease-contraception-non-use-among-adolescents-100592230","NCT06990724","Effectiveness Testing of a Videogame Intervention (No Baby No) to Decrease Contraception Non-use Among Adolescents.","Effectiveness Testing of a Videogame Intervention (No Baby No) to Decrease Contraception Non-use Among Adolescents: A Randomized Trial","Inclusion Criteria:\n\n* Male or Female\n* Age15-20 at the time of enrollment\n* Able to speak and read English or Spanish\n* Have a smart phone (to scan QR code) or personal email account (to take screening questionnaire)\n\nExclusion Criteria:\n\n* Age less than 15 or older than 20\n* Unable to speak and read English or Spanish\n* Do not have a smart phone or personal email account","ALL","20 Years",{"count":55,"type":23},850,[26],"The purpose of this study is to evaluate the effectiveness of a videogame compared to an attention\u002Ftime control at reducing contraceptive non-use among adolescents.",[30,59],"Contraception Behavior","RECRUITING","2025-12-15",{"date":63,"type":36},"2025-12-22",{"date":65,"type":36},"2025-06-11",{"date":67,"type":23},"2027-11",{"name":69,"class":43},"Weill Medical College of Cornell University",7,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":17,"sex":18,"minAge":78,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":24,"phases":82,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":95},"100595987","early-phase-1-assess-performance-attributes-and-acceptability-of-non-medicated-intravaginal-rings-among-sexually-active-women-in-atlanta-ga-100595987","NCT07039591","Assess Performance Attributes and Acceptability of Non-medicated Intravaginal Rings Among Sexually Active Women in Atlanta, GA","A Randomized Open Label Crossover Trial to Assess Performance Attributes and Acceptability of Non-medicated Intravaginal Rings Among Sexually Active Women in Atlanta, GA","Inclusion Criteria:\n\n* 1\\. Cisgender female aged 18-49 years old, inclusive, at screening based on self-report.\n\n  2\\. Sexually active, defined as having penile-vaginal sex at least once a week, on average, over the past three months with the same male partner, and intends to continue having sexual intercourse at the current frequency for at least three months.\n\n  3\\. Healthy based on medical history, physical exam (including pelvic exam with visual inspection) at screening.\n\n  4\\. Using effective non-vaginal method of contraception (oral contraception, injectable, patch, IUD, sterilization, male condoms) 5. Competent to provide written informed consent based on Investigator's assessment.\n\n  6\\. Agrees to not participate in any other clinical research involving investigational or marketed products for the duration of this trial.\n\nExclusion Criteria:\n\n* 1\\. Known or suspected allergy to silicone or EVA, as reported by participant. 2. Positive pregnancy test at screening or enrollment based on urine hCG test. 3. Positive for HIV at screening based on rapid test per site SOPs. 4. Presence of any clinically significant genital epithelial findings (e.g. abrasions, ulcerations, lacerations, or vesicles) at screening.\n\n  5\\. Positive chlamydia, gonorrhea, or trichomoniasis test at screening. 6. Symptomatic vulvovaginal candidiasis, bacterial vaginosis (BV), or urinary tract infection (UTI) at screening. (Participants who are symptomatic at initial screening will be referred for testing and treatment and may be reconsidered for eligibility after completing treatment and\u002For if no longer symptomatic).\n\n  7\\. Presence of genital abnormalities on visual exam with speculum that would contraindicate IVR use.\n\n  8\\. History of significant uterine or vaginal prolapse, or urethral obstruction. 9. Unexplained vaginal bleeding per self-report within the last three months. 10. Currently breastfeeding per self-report. 11. Partial or complete hysterectomy per self-report. 12. History of gynecological surgery in the six months prior to screening per self-report.\n\n  13\\. Within six weeks post abortion or six months postpartum, per self-report. 14. Using vaginal contraception (diaphragm, female condom, spermicide, IVR). 15. Known current drug abuse, including illicit drugs, or alcohol abuse. 16. Any other condition the clinician feels would jeopardize the health and wellbeing of the participant after assessing the participant's potential eligibility for the study.\n\n  17\\. Unable to comply with study requirements, including but not limited to, attending all study visits and using the IVRs as directed.\n\n  18\\. Participation in any other clinical research trial involving investigational or marketed products currently or within one month of participation prior to screening, including any trial of a spermicide, microbicide and\u002For drug.","18 Years","49 Years",{"count":81,"type":23},60,[83],"EARLY_PHASE1","A randomized open label crossover trial to assess performance attributes and acceptability of non-medicated intravaginal rings among sexually active women in Atlanta, GA",[30],"2025-08-28",{"date":88,"type":36},"2025-09-05",{"date":90,"type":36},"2025-08-08",{"date":92,"type":23},"2026-10-30",{"name":94,"class":43},"Population Council",1,{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":102,"eligibilityCriteria":103,"healthyVolunteers":17,"sex":18,"minAge":78,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":24,"phases":106,"briefSummary":107,"conditions":108,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":119},"100568502","telemedicine-contraceptive-counselling-tecc-versus-standard-care-100568502","NCT06682065","Telemedicine Contraceptive Counselling (TECC) Versus Standard Care","Telemedicine Contraceptive Counselling (TECC) Versus Standard Care - a Pilot and Randomized Controlled Trial of Periabortion Contraceptive Counseling","TECC","* Seeking either surgical or medical abortion\n* ≥ 18 years of age\n* Able to communicate and understand spoken and written English\n* With private access to a smart phone\n* Willing to participate in the study procedures",{"count":105,"type":23},510,[26],"Overall purpose of the PILOT and RCT:\n\nThis research project aims to increase access and uptake of contraception after abortion through the systematic development and testing of a new telemedicine service for contraceptive counselling (TECC). The investigators will perform a pilot study in South Africa, and multicenter randomized controlled trial in South Africa and Kenya with the following specific aims:",[30,109],"Telemedicine","2024-11-08",{"date":112,"type":36},"2024-11-12",{"date":114,"type":36},"2024-05-05",{"date":116,"type":23},"2026-02-15",{"name":118,"class":43},"Karolinska Institutet",2,{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":17,"sex":18,"minAge":78,"maxAge":126,"enrollmentInfo":127,"targetDuration":4,"studyType":24,"phases":129,"briefSummary":131,"conditions":132,"keywords":133,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":95},"100491083","phase-4-disparities-in-emergency-contraceptive-metabolism-dictate-efficacy-100491083","NCT05674513","Disparities in Emergency Contraceptive Metabolism Dictate Efficacy","Inclusion Criteria:\n\n* Generally healthy women\n* Aged 18-40\n* regular menses (every 21-35 days) experiencing ovulatory cycles proven by a single progesterone level of 3 ng\u002FmL or greater during the luteal phase of the screening cycle.\n\nExclusion Criteria:\n\n* Pregnant, seeking pregnancy, or breastfeeding\n* Known allergy to study medication\n* Recent use of hormonal contraception\n* Irregular periods (\\\u003C21 days or \\>35 day cycles)\n* Routine use of nonsteroidal anti-inflammatory drugs\n* Metabolic disorders\n* Smoking\n* Any condition that would preclude the provision of informed consent\n* Using drugs (within 2 weeks of study enrollment) known to interfere with the metabolism of UPA as well as drugs known to be CYP3A4 inducers, inhibitors, or CYP3A drug substrates","40 Years",{"count":128,"type":23},140,[130],"PHASE4","The purpose of this study is to learn more about why some people are at greater risk for oral emergency contraceptive failure while others are not. The investigators want to learn if genetic differences impact the risk of emergency contraception failure.",[30],[134,135],"Ulipristal acetate","Emergency contraception","2024-08-16",{"date":138,"type":36},"2024-08-19",{"date":140,"type":36},"2023-01-09",{"date":142,"type":23},"2027-12-31",{"name":144,"class":43},"Oregon Health and Science University"]